Developer docs
API playgroundTry for free, no card

Search company profiles

Darmiyan

Full company profile

uuid0000ecw

Namestring
Darmiyan
Legal namestring
Darmiyan, Inc.
Websiteurl
darmiyan.com
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Darmiyan is a neuroscience-AI company founded in 2016 that develops software for early detection, monitoring, and prognosis of Alzheimer's disease. Its core technology, the DarmiScope Virtual Microscope, performs cellular-level analysis of every voxel (3D pixel) of a standard clinical brain MRI scan to extract novel biomarkers of neurodegeneration, built on four decades of pioneering brain research and protected by patents granted in the US and Japan with filings in Europe and Asia. The flagship commercial product, BrainSee, combines a patient's brain MRI with cognitive test scores to produce a 0–100 score indicating the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia; BrainSee received FDA Breakthrough Device Designation in May 2021 and FDA De Novo approval in January 2024, making it the first FDA-approved medical software in this prognostic indication.

The company serves three primary customer segments: healthcare providers (neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints); pharmaceutical companies seeking objective measures to identify prodromal biomarkers and support Alzheimer's drug development (anchored by Eisai, which led the 2020 Series Seed); and health facilities and senior-care networks, most notably the California Association of Health Facilities (CAHF), which in November 2025 designated Darmiyan as its preferred provider for cognitive health solutions across member facilities serving 350,000+ California residents. Distribution is enterprise field sales with direct engagement of hospitals, clinics, and MR imaging centers, supplemented by clinical validation partnerships with academic medical centers (Banner Alzheimer's Institute, Baycrest, UHN, Hamilton Health Sciences).

Revenue mechanics center on recurring licensing of the BrainSee diagnostic software to healthcare providers, supplemented by pharmaceutical partnerships for drug development support. The company is privately held, headquartered in Emeryville, CA with an additional Toronto office for Canadian business development, and operates with a small team (1–10 FTE). Strategic capital has come from Eisai (2020 Series Seed lead), SOMPO (2022), IT-Farm, and others, with total disclosed funding in the $10M+ range across multiple rounds.

Short descriptiontext

Darmiyan is a neuroscience-AI company whose FDA De Novo-approved BrainSee software (January 2024) provides the first AI-powered prognosis of Alzheimer's disease in patients with amnestic mild cognitive impairment, using its proprietary DarmiScope MRI analysis platform to serve healthcare providers, pharmaceutical companies, and senior-care networks.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
medical imaging AI, Alzheimer's diagnostics, brain health software, MRI analysis, neurodegenerative disease detection
Industry3 codes
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code3 codes
  • Services-Prepackaged Software7372
  • Services-Medical Laboratories8071
  • Laboratory Analytical Instruments3826
Product category
AI Medical Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1BrainSee Diagnostic Software
TypeSubscription Recurring
Description

Revenue generated from licensing BrainSee AI diagnostic software to healthcare providers for clinical evaluation of patients with mild cognitive impairment. The software helps physicians determine prognosis and likelihood of progression to Alzheimer's dementia.

darmiyan.com
2Pharmaceutical Partnerships
TypeLicensing Royalties
Description

Using data to advance drug development for Alzheimer's disease. Partnerships with pharmaceutical companies for drug development support using the company's brain imaging and AI technology.

darmiyan.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Others
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 record
1BrainSee
Description

FDA-approved AI medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). BrainSee combines a patient's brain MRI with cognitive test scores to generate a score between 0 and 100 indicating likelihood of progression from MCI to Alzheimer's dementia.

darmiyan.com
Core offering1 text field

Darmiyan develops and licenses BrainSee, the first FDA-approved (De Novo, January 2024) AI-powered medical software that helps physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). The software combines a patient's standard clinical brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. The technology is powered by DarmiScope, a patented Virtual Microscope that performs cellular-level quantification within every voxel of brain MRI scans with approximately 90% accuracy in predicting 5-year clinical prognosis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • ~90% accuracy in predicting 5-year clinical prognosis of MCI (blind testing of 411 cases with 5 years follow-up)
+2 more records
Product overview1 text field

Darmiyan offers a unified platform focused on precision brain health screening and monitoring. The company's flagship product is BrainSee, an FDA-approved (De Novo, January 2024) AI-powered medical software that provides early detection and prognosis of Alzheimer's disease. BrainSee is powered by DarmiScope, the company's proprietary core technology that acts as a 'virtual microscope' analyzing brain MRI scans at the cellular level. BrainSee combines brain imaging with cognitive test scores to generate prognostic scores for patients with amnestic mild cognitive impairment. The company is developing additional brain tests as part of an 'a la carte menu of brain tests' starting with Alzheimer's testing, with technology applicable to other neurodegenerative disorders.

Product and service2 records
1BrainSee
CategoryAI Diagnostic Software
Description

BrainSee is the first FDA-approved (De Novo, January 2024) AI-powered medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). It combines a patient's brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. It received FDA Breakthrough Device Designation in May 2021 and is designed for neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints.

2DarmiScope Virtual Microscope
CategoryCore Technology Platform
Description

DarmiScope is the patented core Virtual Microscope technology that resolves tissue structure in every voxel of brain MRI, performing cellular-level quantification with approximately 90% accuracy to predict 5-year clinical prognosis of MCI. It is the foundational technology behind BrainSee and has applications across neurodegenerative disorders.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership7 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

CAHF designated Darmiyan as its preferred provider for cognitive health solutions, offering its members access to the FDA-approved AI tool BrainSee. This partnership aims to enhance early assessment and prevention of dementia among over 350,000 residents across California facilities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership with CABHI includes collaboration with partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences. Darmiyan won CABHI Innovation Award in 2019 and CABHI Industry Innovation (I2P2) award in 2018 for CAN $500K.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Proof of concept study focused on early detection of Alzheimer's disease at preclinical (presymptomatic) stage. Partnership agreement signed in 2018 Q1.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Partnership agreement signed with Boston University in 2018 Q2 for collaboration in research and development.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Strategic partnership signed in 2019 Q3 with Mary Furlong & Associates for business development and marketing support in the longevity and brain health sector.

Strategic tierCoreTypeGTM or Marketing Partner
Description

Content partnership launched in 2021 Q4 with Medscape, a leading medical information platform, to provide brain health educational content to physicians.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Mounted brain health content series with GetSetup adult learning platform featuring Chief Medical and Technology Officer Dr. Kaveh Vejdani, yielding record registration levels.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Altoida develops a digital cognitive assessment platform using smartphone-based AR/AI tests to detect early signs of cognitive decline and predict conversion to AD. It targets the same early-MCI detection workflow as BrainSee but via cognitive testing rather than MRI.

TypeDirect peer
Description

Cogstate provides computerized cognitive testing for clinical trials, healthcare providers, and research, including AD/MCI assessment. It is comparable to Darmiyan in supplying objective cognitive measurement to clinicians evaluating MCI patients and to pharma for trial endpoints.

TypeDirect peer
Description

Quanterix's Simoa platform provides ultra-sensitive biomarker detection (including p-tau217, NfL) used for Alzheimer's disease diagnosis and monitoring. It competes with BrainSee in the objective early-detection-of-AD space, offering a complementary non-imaging modality.

TypeBroad incumbent
Description

Clario is a large clinical-trial technology and imaging CRO that provides MRI analysis and clinical-readout services to pharma sponsors, including for AD trials. It is comparable as an established pharma-services partner offering imaging-based AD endpoints, though broader in scope than Darmiyan's diagnostic focus.

TypeDirect peer
Description

C2N Diagnostics commercializes PrecivityAD, a blood-based Alzheimer's diagnostic that, like BrainSee, addresses the early detection and prognosis of AD from a non-invasive specimen. Both companies are pursuing FDA-cleared prognostic tools for the MCI-to-AD conversion pathway.

TypeDirect peer
Description

QMENTA operates an AI-powered neuroimaging platform for clinical trials and clinical practice, including brain MRI analysis for neurological disorders. It overlaps with Darmiyan in providing cloud-based brain imaging AI infrastructure to pharma and research institutions.

TypeDirect peer
Description

icometrix provides AI-based brain MRI analysis software (MSmetrix, icobrain) for quantification and monitoring of neurological conditions including MS, dementia, and TBI. It is a direct peer in AI-powered brain MRI SaaS sold to clinicians and pharma for neurodegenerative disease management.

TypeDirect peer
Description

Cerveau develops and supplies tau PET imaging ligands used in Alzheimer's disease diagnosis and clinical trials. Like Darmiyan, Cerveau's tools are deployed to identify early/prodromal AD pathology and support pharmaceutical drug development programs.

TypeDirect peer
Description

Cortechs.ai markets NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool used clinically to support neurological diagnosis and monitoring. Like Darmiyan, Cortechs applies AI/quantitative analysis to standard clinical brain MRI for neurodegenerative disease assessment.

TypeDirect peer
Description

Linus Health offers a digital cognitive assessment platform (incorporating DCTclock and other AI-based pen-and-paper tests) for early detection of cognitive impairment. It addresses the same primary care / memory clinic workflow as BrainSee for MCI evaluation.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors16 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Darmiyan

AI Medical Diagnosticsdarmiyan.com

Darmiyan is a neuroscience-AI company whose FDA De Novo-approved BrainSee software (January 2024) provides the first AI-powered prognosis of Alzheimer's disease in patients with amnestic mild cognitive impairment, using its proprietary DarmiScope MRI analysis platform to serve healthcare providers, pharmaceutical companies, and senior-care networks.

What Darmiyan does

Darmiyan is a neuroscience-AI company founded in 2016 that develops software for early detection, monitoring, and prognosis of Alzheimer's disease. Its core technology, the DarmiScope Virtual Microscope, performs cellular-level analysis of every voxel (3D pixel) of a standard clinical brain MRI scan to extract novel biomarkers of neurodegeneration, built on four decades of pioneering brain research and protected by patents granted in the US and Japan with filings in Europe and Asia. The flagship commercial product, BrainSee, combines a patient's brain MRI with cognitive test scores to produce a 0–100 score indicating the likelihood of progression from amnestic mild cognitive impairment (aMCI) to Alzheimer's dementia; BrainSee received FDA Breakthrough Device Designation in May 2021 and FDA De Novo approval in January 2024, making it the first FDA-approved medical software in this prognostic indication.

The company serves three primary customer segments: healthcare providers (neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints); pharmaceutical companies seeking objective measures to identify prodromal biomarkers and support Alzheimer's drug development (anchored by Eisai, which led the 2020 Series Seed); and health facilities and senior-care networks, most notably the California Association of Health Facilities (CAHF), which in November 2025 designated Darmiyan as its preferred provider for cognitive health solutions across member facilities serving 350,000+ California residents. Distribution is enterprise field sales with direct engagement of hospitals, clinics, and MR imaging centers, supplemented by clinical validation partnerships with academic medical centers (Banner Alzheimer's Institute, Baycrest, UHN, Hamilton Health Sciences).

Revenue mechanics center on recurring licensing of the BrainSee diagnostic software to healthcare providers, supplemented by pharmaceutical partnerships for drug development support. The company is privately held, headquartered in Emeryville, CA with an additional Toronto office for Canadian business development, and operates with a small team (1–10 FTE). Strategic capital has come from Eisai (2020 Series Seed lead), SOMPO (2022), IT-Farm, and others, with total disclosed funding in the $10M+ range across multiple rounds.

Darmiyan firmographics

Firmographics
Name
Darmiyan
Legal name
Darmiyan, Inc.
Website
https://darmiyan.com
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
11–50 employees
Short description
Darmiyan is a neuroscience-AI company whose FDA De Novo-approved BrainSee software (January 2024) provides the first AI-powered prognosis of Alzheimer's disease in patients with amnestic mild cognitive impairment, using its proprietary DarmiScope MRI analysis platform to serve healthcare providers, pharmaceutical companies, and senior-care networks.
Ownership category
akta.pro rank

Darmiyan industry classification

Industry
Product category
AI Medical Diagnostics
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Prepackaged Software (7372), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)
akta.pro industry
PRIMARYHLACANAG
SaMD – Imaging & Signal Analysis (AI/ML)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAAALAO
Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays)

Keywords

  • Medical imaging AI
  • Alzheimer's diagnostics
  • Brain health software
  • MRI analysis
  • Neurodegenerative disease detection

Where Darmiyan is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Offices3 records

Markets served

Darmiyan business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Others

Revenue model

  1. BrainSee Diagnostic Software: Revenue generated from licensing BrainSee AI diagnostic software to healthcare providers for clinical evaluation of patients with mild cognitive impairment. The software helps physicians determine prognosis and likelihood of progression to Alzheimer's dementia.
  2. Pharmaceutical Partnerships: Using data to advance drug development for Alzheimer's disease. Partnerships with pharmaceutical companies for drug development support using the company's brain imaging and AI technology.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Darmiyan product offering

Product offering

Core offering

Darmiyan develops and licenses BrainSee, the first FDA-approved (De Novo, January 2024) AI-powered medical software that helps physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). The software combines a patient's standard clinical brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. The technology is powered by DarmiScope, a patented Virtual Microscope that performs cellular-level quantification within every voxel of brain MRI scans with approximately 90% accuracy in predicting 5-year clinical prognosis.

Product overview

Darmiyan offers a unified platform focused on precision brain health screening and monitoring. The company's flagship product is BrainSee, an FDA-approved (De Novo, January 2024) AI-powered medical software that provides early detection and prognosis of Alzheimer's disease. BrainSee is powered by DarmiScope, the company's proprietary core technology that acts as a 'virtual microscope' analyzing brain MRI scans at the cellular level. BrainSee combines brain imaging with cognitive test scores to generate prognostic scores for patients with amnestic mild cognitive impairment. The company is developing additional brain tests as part of an 'a la carte menu of brain tests' starting with Alzheimer's testing, with technology applicable to other neurodegenerative disorders.

Differentiator

Problem solved

Functional benefit

Brands

  • BrainSee: FDA-approved AI medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). BrainSee combines a patient's brain MRI with cognitive test scores to generate a score between 0 and 100 indicating likelihood of progression from MCI to Alzheimer's dementia.

Products and services

  • BrainSee BrainSee is the first FDA-approved (De Novo, January 2024) AI-powered medical software designed to help physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). It combines a patient's brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. It received FDA Breakthrough Device Designation in May 2021 and is designed for neurologists, radiologists, neuroradiologists, and primary care physicians evaluating patients with memory complaints.
  • DarmiScope Virtual Microscope DarmiScope is the patented core Virtual Microscope technology that resolves tissue structure in every voxel of brain MRI, performing cellular-level quantification with approximately 90% accuracy to predict 5-year clinical prognosis of MCI. It is the foundational technology behind BrainSee and has applications across neurodegenerative disorders.

Quantifiable outcome

  • ~90% accuracy in predicting 5-year clinical prognosis of MCI (blind testing of 411 cases with 5 years follow-up)
  • +2 more outcomes

Companies that use Darmiyan

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Darmiyan technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature4 records

Darmiyan partnerships and signals

Strategic signal

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

  • California Association of Health Facilities (CAHF)flagshipStrategic or Co-development Partner · 6 November 2025CAHF designated Darmiyan as its preferred provider for cognitive health solutions, offering its members access to the FDA-approved AI tool BrainSee. This partnership aims to enhance early assessment and prevention of dementia among over 350,000 residents across California facilities.
  • Center for Aging and Brain Health Innovation (CABHI)coreStrategic or Co-development PartnerPartnership with CABHI includes collaboration with partner sites Baycrest Institute, University Health Network (UHN) and Hamilton Health Sciences. Darmiyan won CABHI Innovation Award in 2019 and CABHI Industry Innovation (I2P2) award in 2018 for CAN $500K.
  • Banner Alzheimer's InstitutecoreStrategic or Co-development PartnerProof of concept study focused on early detection of Alzheimer's disease at preclinical (presymptomatic) stage. Partnership agreement signed in 2018 Q1.
  • Boston UniversityminorStrategic or Co-development PartnerPartnership agreement signed with Boston University in 2018 Q2 for collaboration in research and development.
  • Mary Furlong & AssociatescoreGTM or Marketing PartnerStrategic partnership signed in 2019 Q3 with Mary Furlong & Associates for business development and marketing support in the longevity and brain health sector.
  • MedscapecoreGTM or Marketing PartnerContent partnership launched in 2021 Q4 with Medscape, a leading medical information platform, to provide brain health educational content to physicians.
  • GetSetupminorGTM or Marketing PartnerMounted brain health content series with GetSetup adult learning platform featuring Chief Medical and Technology Officer Dr. Kaveh Vejdani, yielding record registration levels.

Scale indicators7 records

Recent moves7 records

Expansion highlights6 records

Darmiyan competitors and assessment

Company assessment

Direct peers

  • Altoida: Altoida develops a digital cognitive assessment platform using smartphone-based AR/AI tests to detect early signs of cognitive decline and predict conversion to AD. It targets the same early-MCI detection workflow as BrainSee but via cognitive testing rather than MRI.
  • Cogstate: Cogstate provides computerized cognitive testing for clinical trials, healthcare providers, and research, including AD/MCI assessment. It is comparable to Darmiyan in supplying objective cognitive measurement to clinicians evaluating MCI patients and to pharma for trial endpoints.
  • Quanterix: Quanterix's Simoa platform provides ultra-sensitive biomarker detection (including p-tau217, NfL) used for Alzheimer's disease diagnosis and monitoring. It competes with BrainSee in the objective early-detection-of-AD space, offering a complementary non-imaging modality.
  • C2N Diagnostics: C2N Diagnostics commercializes PrecivityAD, a blood-based Alzheimer's diagnostic that, like BrainSee, addresses the early detection and prognosis of AD from a non-invasive specimen. Both companies are pursuing FDA-cleared prognostic tools for the MCI-to-AD conversion pathway.
  • QMENTA: QMENTA operates an AI-powered neuroimaging platform for clinical trials and clinical practice, including brain MRI analysis for neurological disorders. It overlaps with Darmiyan in providing cloud-based brain imaging AI infrastructure to pharma and research institutions.
  • icometrix: icometrix provides AI-based brain MRI analysis software (MSmetrix, icobrain) for quantification and monitoring of neurological conditions including MS, dementia, and TBI. It is a direct peer in AI-powered brain MRI SaaS sold to clinicians and pharma for neurodegenerative disease management.
  • Cerveau Technologies: Cerveau develops and supplies tau PET imaging ligands used in Alzheimer's disease diagnosis and clinical trials. Like Darmiyan, Cerveau's tools are deployed to identify early/prodromal AD pathology and support pharmaceutical drug development programs.
  • Cortechs.ai: Cortechs.ai markets NeuroQuant, an FDA-cleared MRI brain volumetric analysis tool used clinically to support neurological diagnosis and monitoring. Like Darmiyan, Cortechs applies AI/quantitative analysis to standard clinical brain MRI for neurodegenerative disease assessment.
  • Linus Health: Linus Health offers a digital cognitive assessment platform (incorporating DCTclock and other AI-based pen-and-paper tests) for early detection of cognitive impairment. It addresses the same primary care / memory clinic workflow as BrainSee for MCI evaluation.

Broad incumbents

  • Clario (formerly Bioclinica): Clario is a large clinical-trial technology and imaging CRO that provides MRI analysis and clinical-readout services to pharma sponsors, including for AD trials. It is comparable as an established pharma-services partner offering imaging-based AD endpoints, though broader in scope than Darmiyan's diagnostic focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks7 records

Key highlights7 records

Customer concentration

Darmiyan social profiles

Digital presence

Darmiyan compliance and trust

Trust signal

Compliance1 record

Darmiyan financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Darmiyan leadership team

Management profile

Number of profiles

Profiles8 records

Darmiyan funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Darmiyan M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Darmiyan

What does Darmiyan do?

Darmiyan develops and licenses BrainSee, the first FDA-approved (De Novo, January 2024) AI-powered medical software that helps physicians evaluate the prognosis of patients diagnosed with amnestic mild cognitive impairment (aMCI). The software combines a patient's standard clinical brain MRI with cognitive test scores and generates a score between 0 and 100 indicating the likelihood of progression from MCI to Alzheimer's dementia. The technology is powered by DarmiScope, a patented Virtual Microscope that performs cellular-level quantification within every voxel of brain MRI scans with approximately 90% accuracy in predicting 5-year clinical prognosis.

Is Darmiyan a public or private company?

Darmiyan is a private company. It is classified as venture growth investor backed and is currently operating.

When was Darmiyan founded?

Darmiyan was founded in 2016. It employs 11 to 50 people.

Where is Darmiyan based?

Darmiyan is headquartered in San Francisco, United States, in the North America region.

How does Darmiyan make money?

Two revenue lines are on record. BrainSee Diagnostic Software is the primary driver. The others are pharmaceutical Partnerships.

Who are Darmiyan's main competitors?

Direct peers on record are Altoida, Cogstate, Quanterix, C2N Diagnostics, QMENTA, icometrix, Cerveau Technologies, Cortechs.ai and Linus Health. Clario (formerly Bioclinica) is listed as a broad incumbent.

Does Darmiyan have an API?

No public API is recorded for Darmiyan.

What industry is Darmiyan in?

Darmiyan's product category is AI Medical Diagnostics. Its primary akta.pro industry code is HLACANAG, SaMD – Imaging & Signal Analysis (AI/ML), with a secondary code of HDAAAEAH, Medical Imaging AI. Its NAICS code is 621511 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Neurology liveFDA Grants Approval of Darmiyan's BrainSee Test for Predicting Progression of Alzheimer DiseaseThe FDA has granted approval for Darmiyan's BrainSee, a software platform that uses AI to predict the progression of amnestic mild cognitive impairment to Alzheimer's disease. This marks the first regulatory approval for this specific prognostic test, which analyzes brain MRI and cognitive assessments to generate objective scores over a five-year period. The company states the test addresses a critical unmet need for millions of patients globally by offering a noninvasive alternative to invasive biomarker methods.NewsfileRhelion Life Sciences' Wholly Owned Subsidiary Filament Health Signs Letter of Intent with Darmiyan, Inc. to Explore Use of FDA De Novo Authorized BrainSee(R) AI Platform in Early Alzheimer's DiseaseRhelion Life Sciences' subsidiary Filament Health has signed a non-binding letter of intent with Darmiyan, Inc. to explore collaborating on the use of Darmiyan's FDA-authorized BrainSee AI platform for patient selection in clinical trials of Rhelion's psilocybin drug candidate PEX010. The collaboration aims to leverage AI-enabled imaging to potentially reduce trial size, duration, and costs while improving the identification of candidates at risk of progressing from mild cognitive impairment to Alzheimer's disease. This strategic partnership represents an effort to apply novel neuroplasticity research and advanced diagnostic tools to address the significant challenges in early Alzheimer's treatment development.Stock TitanRhelion Signs LOI to Explore FDA-Authorized AI PlatformRhelion Life Sciences' subsidiary, Filament Health, signed a letter of intent to collaborate with Darmiyan, Inc. to explore using Darmiyan's FDA-authorized BrainSee AI platform for patient selection in clinical trials for Rhelion's psilocybin drug candidate PEX010. The partnership aims to leverage AI-enabled imaging to potentially reduce the size and duration of early Alzheimer's disease trials while improving the likelihood of detecting treatment effects.PluangRhelion and Darmiyan collaborate to use AI brai...Rhelion Life Sciences' subsidiary Filament Health has signed a letter of intent with Darmiyan to integrate Darmiyan's FDA-authorized AI brain imaging platform, BrainSee, into clinical trials for Rhelion's psilocybin candidate PEX010. This collaboration aims to improve patient selection and trial efficiency by predicting Alzheimer's progression risk, potentially reducing trial size and duration. The partnership represents an innovative approach combining AI technology with psychedelic treatments in Alzheimer's research.MedTech WorldDarmiyan’s BrainSee Wins FDA Approval for Post-Market Surveillance Study to Advance Alzheimer’s PrognosisDarmiyan has secured FDA approval for a seven-year post-market surveillance study to validate the safety and effectiveness of its AI-powered BrainSee tool for predicting Alzheimer's progression. The study will partner with major research institutions to assess the tool's utility in diverse patient populations across the United States. This initiative aims to improve clinical practice and assist pharmaceutical companies in identifying suitable candidates for future Alzheimer's treatments.NewswiseDarmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer's DiseaseDarmiyan, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved its post-market surveillance study for BrainSee, an AI-powered clinical test for predicting Alzheimer's disease progression. The seven-year study aims to validate the tool's safety and effectiveness in diverse populations while supporting pharmaceutical companies in identifying optimal candidates for clinical trials. This approval follows the marketing authorization granted in January 2024, positioning BrainSee as a non-invasive prognostic tool distinct from traditional biomarker tests.PR NewswireDarmiyan Receives FDA Approval for Post-Market Surveillance Study of BrainSee, the First-in-Class Clinical Test for Predicting Risk of Progression to Clinical Alzheimer's DiseaseDarmiyan, Inc., a San Francisco-based brain health technology company, announced that the U.S. Food and Drug Administration has approved a 7-year post-market surveillance study for BrainSee, its AI-powered prognostic tool that predicts progression from amnestic mild cognitive impairment to clinical Alzheimer's disease within five years. BrainSee received FDA marketing authorization in January 2024 via the De Novo pathway as the first and only FDA-approved non-invasive technology that combines standard brain MRI, cognitive assessments, age, and biological sex to generate prognostic scores for patients over 55. The study will collect data from socio-demographically diverse patient populations across U.S. community clinics and hospitals, collaborating with leading Alzheimer's Disease Research Centers including NACC, HABS-HD, ADNI, UAB ADRC, UC Davis ADRC, and OASIS, to further validate clinical utility and support pharmaceutical trial recruitment.PR NewswireMCRA Supports Darmiyan with FDA Approval for BrainSee DeviceMCRA, a clinical research organization, announced its role in helping Darmiyan secure FDA De Novo approval for BrainSee, a first-of-a-kind AI-powered medical device, in January 2024. BrainSee analyzes brain MRIs combined with cognitive test results to predict the likelihood of progression from mild cognitive impairment to Alzheimer's dementia within five years. MCRA had been working with Darmiyan since 2021 to achieve Breakthrough Device Designation and navigate the FDA regulatory process.AlzheimersnewstodayBrainSee to predict Alzheimer’s dementia now approved by FDAThe U.S. Food and Drug Administration has approved BrainSee, an AI-based software developed by Darmiyan, for predicting the likelihood of progression from mild cognitive impairment to Alzheimer’s dementia. The technology analyzes brain MRI data and cognitive test scores with reported 91% accuracy in clinical studies, offering a non-invasive alternative to current diagnostic methods. This approval aims to facilitate earlier treatment initiation and reduce the burden of costly, invasive testing.NotebookcheckDarmiyan BrainSee medical AI software granted FDA approval for use indicating Alzheimer’s disease likelihood using MRI brain scans and cognitive test scoresThe FDA granted De Novo approval to Darmiyan's BrainSee, a medical AI software that uses MRI brain scans and cognitive test scores to predict the likelihood of Alzheimer's disease within five years. This approval marks the first prognostic test for predicting progression from amnestic mild cognitive impairment to Alzheimer's dementia, aiming to enable early intervention and reduce reliance on invasive biomarker tests.